4.5 Article

Mass cytometry reveals immune signatures associated with cytomegalovirus (CMV) control in recipients of allogeneic haemopoietic stem cell transplant and CMV-specific T cells

期刊

出版社

WILEY
DOI: 10.1002/cti2.1149

关键词

adoptive T-cell therapy; CyTOF; haemopoietic stem cell transplant; immune reconstitution; immunotherapy; mass cytometry

资金

  1. Australian National Health and Medical Research Council (NHMRC) [GNT1121643, GNT1032431]
  2. Australian Leukaemia Foundation
  3. Cancer Council of NSW
  4. Royal College of Pathologists of Australasia
  5. NSW Cancer Institute
  6. NHMRC [GNT1089398, GNT1037298, GNT1128417]
  7. Australian Postgraduate Award
  8. International Society for the Advancement of Cytometry (ISAC) Marylou Ingram Scholars Program - Sydney Medical School Kickstart
  9. Sydney Medical School BioMed-Connect

向作者/读者索取更多资源

Objectives. Cytomegalovirus (CMV) is known to have a significant impact on immune recovery post-allogeneic haemopoietic stem cell transplant (HSCT). Adoptive therapy with donor-derived or third-party virus-specific T cells (VST) can restore CMV immunity leading to clinical benefit in prevention and treatment of post-HSCT infection. We developed a mass cytometry approach to study natural immune recovery post-HSCT and assess the mechanisms underlying the clinical benefits observed in recipients of VST. Methods A mass cytometry panel of 38 antibodies was utilised for global immune assessment (72 canonical innate and adaptive immune subsets) in HSCT recipients undergoing natural post-HSCT recovery (n = 13) and HSCT recipients who received third-party donor-derived CMV-VST as salvage for unresponsive CMV reactivation (n = 8). Results Mass cytometry identified distinct immune signatures associated with CMV characterised by a predominance of innate cells (monocytes and NK) seen early and an adaptive signature with activated CD8(+)T cells seen later. All CMV-VST recipients had failed standard antiviral pharmacotherapy as a criterion for trial involvement; 5/8 had failed to develop the adaptive immune signature by study enrolment despite significant CMV antigen exposure. Of these, VST administration resulted in development of the adaptive signature in association with CMV control in three patients. Failure to respond to CMV-VST in one patient was associated with persistent absence of the adaptive immune signature. Conclusion The clinical benefit of CMV-VST may be mediated by the recovery of an adaptive immune signature characterised by activated CD8(+)T cells.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据